Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 721 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Health inequalities: Why is it harder for some people to eat... June 24, 2022 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 A toolkit to address disparities in digitally enabled oncology trials September 5, 2025 Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Load more HOT NEWS Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... Training Cancer Researchers: A Conversation with Dr. Oliver Bogler Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020...
